The purpose of this trial is to determine if ER OROS Paliperidone is an effective treatment for adults with acute schizophrenia.

Condition	Treatment or Intervention	Phase
Schizophrenia	Drug: ER OROS Paliperidone	Phase III

Further Study Details: 

Expected Total Enrollment:  440

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

• Age must be 18 years of age or older.
• Subjects must have been diagnosed with schizophrenia according to DSM-IV (295.10, 295.20, 295.30, 295.60, 295.90) at least 1 year prior to screening.
• Subjects must be experiencing an acute episode, with a total PANSS score at screening between 70 and 120.
• Subjects must agree to voluntary hospitalization for a minimum of 14 days.

Louisiana
      J. Gary Booker, MD, Shreveport,  Louisiana,  71101,  United States

Study ID Numbers:  R076477-SCH-304; schizophrenia
Record last reviewed:  November 2004
Last Updated:  November 19, 2004
Record first received:  February 11, 2004
ClinicalTrials.gov Identifier:  NCT00077714
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08